VANCOUVER, Washington, July 15, 2020 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), an advanced-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential for multiple therapeutic indications, announced today that it recently submitted a complete listing request package with The Nasdaq Stock Market to …
Read More »CytoDyn file application with Nasdaq for top list OTC markets: CYDY
